All In Biotech

Drug Trial Radar · NCT01895972

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Jul 5, 2013

Primary completion

Apr 2, 2015

Study completion Apr 14, 2015

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jul 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • Latanoprostene bunodDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Intraocular PressureTime frame: Baseline and week 4,8,12,16,20,24,28,32,36,40,44,48,52
  2. Clinical SafetyTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb Incorporated

    Bridgewater, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.